Physician profile
John Chece
NPI 1003229923
$2,860.60
in general payments reported to CMS, 2019-2025
25 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,262 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,860.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $452.06 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $402.94 | 2024-2025 | |
| Novo Nordisk INC | $311.55 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $309.04 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $185.99 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $161.18 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $150.33 | 2024-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $149.44 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $121.60 | 2024 | Voquezna |
| Abbott Laboratories | $109.47 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.83 | 2024-2025 | Jardiance |
| Lundbeck LLC | $62.51 | 2024-2025 | Rexulti |
| Edwards Lifesciences Corporation | $45.63 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $33.52 | 2024-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $33.32 | 2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $33.23 | 2024 | Eliquis |
| Astellas Pharma US INC | $30.17 | 2024 | Veozah |
| Verona Pharma, INC. | $26.91 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $26.77 | 2025 | Opsumit, Uptravi |
| Alk-Abello, INC | $26.12 | 2025 | Neffy |
| Corcept Therapeutics | $25.26 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $23.18 | 2024 | Gemtesa |
| Lucid Diagnostics INC. | $18.46 | 2024 | |
| Xeris Pharmaceuticals, INC. | $16.85 | 2025 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $15.24 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chece listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.